AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the shares very undervalued. The post Down 13% from its year high at £116.50 now, ...

In the closing of the recent trading day, Astrazeneca (AZN) stood at $76.21, denoting a +0.74% change from the preceding trading day.

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100’s biggest company is just too pricey. When investing, your capital is at risk.

AstraZeneca PLC (LON:AZN) announced a healthy earnings result recently, and the market rewarded it with a strong uplift in ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the shares very undervalued. When investing, your capital is at risk.

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...